
EquityIndex FundsVery High Risk
Direct
NAV (10-Dec-25)
Returns (Since Inception)
Fund Size
₹161 Cr
Expense Ratio
0.50%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.81%
— (Cat Avg.)
Since Inception
+15.70%
— (Cat Avg.)
| Equity | ₹161.36 Cr | 100.00% |
| Others | ₹0 Cr | 0.00% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Lupin Ltd | Equity | ₹15.09 Cr | 9.35% |
| Fortis Healthcare Ltd | Equity | ₹14.35 Cr | 8.89% |
| Laurus Labs Ltd | Equity | ₹12.01 Cr | 7.44% |
| Aurobindo Pharma Ltd | Equity | ₹10.28 Cr | 6.37% |
| Alkem Laboratories Ltd | Equity | ₹9.59 Cr | 5.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹8.78 Cr | 5.44% |
| Mankind Pharma Ltd | Equity | ₹7.63 Cr | 4.73% |
| Biocon Ltd | Equity | ₹7.17 Cr | 4.44% |
| Ipca Laboratories Ltd | Equity | ₹6.05 Cr | 3.75% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹5.06 Cr | 3.13% |
| Abbott India Ltd | Equity | ₹4.7 Cr | 2.91% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹4.51 Cr | 2.79% |
| Neuland Laboratories Ltd | Equity | ₹4.44 Cr | 2.75% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹4.32 Cr | 2.68% |
| Gland Pharma Ltd | Equity | ₹4.2 Cr | 2.60% |
| Narayana Hrudayalaya Ltd | Equity | ₹3.96 Cr | 2.45% |
| Syngene International Ltd | Equity | ₹3.68 Cr | 2.28% |
| Dr. Lal PathLabs Ltd | Equity | ₹3.49 Cr | 2.16% |
| Piramal Pharma Ltd | Equity | ₹3.47 Cr | 2.15% |
| Ajanta Pharma Ltd | Equity | ₹3.23 Cr | 2.00% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹3.19 Cr | 1.98% |
| Global Health Ltd | Equity | ₹3.15 Cr | 1.95% |
| Wockhardt Ltd | Equity | ₹3.06 Cr | 1.89% |
| OneSource Specialty Pharma Ltd | Equity | ₹2.54 Cr | 1.57% |
| Granules India Ltd | Equity | ₹2.42 Cr | 1.50% |
| Natco Pharma Ltd | Equity | ₹2.35 Cr | 1.46% |
| Pfizer Ltd | Equity | ₹2.26 Cr | 1.40% |
| Poly Medicure Ltd | Equity | ₹2.22 Cr | 1.37% |
| Cohance Lifesciences Ltd | Equity | ₹2.16 Cr | 1.34% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.02 Cr | 1.25% |
| A) Repo | Cash - Repurchase Agreement | ₹0.18 Cr | 0.11% |
| Net Current Liabilities | Cash - Collateral | ₹-0.18 Cr | 0.11% |
Large Cap Stocks
14.08%
Mid Cap Stocks
53.58%
Small Cap Stocks
32.34%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹161.36 Cr | 100.00% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since December 2024
Since July 2025
ISIN INF277KA1BG3 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹161 Cr | Age 1 year 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,20,555 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk


EquityIndex FundsVery High Risk
Direct
NAV (10-Dec-25)
Returns (Since Inception)
Fund Size
₹161 Cr
Expense Ratio
0.50%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.81%
— (Cat Avg.)
Since Inception
+15.70%
— (Cat Avg.)
| Equity | ₹161.36 Cr | 100.00% |
| Others | ₹0 Cr | 0.00% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Lupin Ltd | Equity | ₹15.09 Cr | 9.35% |
| Fortis Healthcare Ltd | Equity | ₹14.35 Cr | 8.89% |
| Laurus Labs Ltd | Equity | ₹12.01 Cr | 7.44% |
| Aurobindo Pharma Ltd | Equity | ₹10.28 Cr | 6.37% |
| Alkem Laboratories Ltd | Equity | ₹9.59 Cr | 5.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹8.78 Cr | 5.44% |
| Mankind Pharma Ltd | Equity | ₹7.63 Cr | 4.73% |
| Biocon Ltd | Equity | ₹7.17 Cr | 4.44% |
| Ipca Laboratories Ltd | Equity | ₹6.05 Cr | 3.75% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹5.06 Cr | 3.13% |
| Abbott India Ltd | Equity | ₹4.7 Cr | 2.91% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹4.51 Cr | 2.79% |
| Neuland Laboratories Ltd | Equity | ₹4.44 Cr | 2.75% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹4.32 Cr | 2.68% |
| Gland Pharma Ltd | Equity | ₹4.2 Cr | 2.60% |
| Narayana Hrudayalaya Ltd | Equity | ₹3.96 Cr | 2.45% |
| Syngene International Ltd | Equity | ₹3.68 Cr | 2.28% |
| Dr. Lal PathLabs Ltd | Equity | ₹3.49 Cr | 2.16% |
| Piramal Pharma Ltd | Equity | ₹3.47 Cr | 2.15% |
| Ajanta Pharma Ltd | Equity | ₹3.23 Cr | 2.00% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹3.19 Cr | 1.98% |
| Global Health Ltd | Equity | ₹3.15 Cr | 1.95% |
| Wockhardt Ltd | Equity | ₹3.06 Cr | 1.89% |
| OneSource Specialty Pharma Ltd | Equity | ₹2.54 Cr | 1.57% |
| Granules India Ltd | Equity | ₹2.42 Cr | 1.50% |
| Natco Pharma Ltd | Equity | ₹2.35 Cr | 1.46% |
| Pfizer Ltd | Equity | ₹2.26 Cr | 1.40% |
| Poly Medicure Ltd | Equity | ₹2.22 Cr | 1.37% |
| Cohance Lifesciences Ltd | Equity | ₹2.16 Cr | 1.34% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.02 Cr | 1.25% |
| A) Repo | Cash - Repurchase Agreement | ₹0.18 Cr | 0.11% |
| Net Current Liabilities | Cash - Collateral | ₹-0.18 Cr | 0.11% |
Large Cap Stocks
14.08%
Mid Cap Stocks
53.58%
Small Cap Stocks
32.34%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹161.36 Cr | 100.00% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since December 2024
Since July 2025
ISIN INF277KA1BG3 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹161 Cr | Age 1 year 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,20,555 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments